New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment
PRESS RELEASE New Studies Show MammaPrint® and BluePrint® Tests Provide Read More
PRESS RELEASE New Studies Show MammaPrint® and BluePrint® Tests Provide Read More
PRESS RELEASE Agendia Announces New Research Reinforcing MammaPrint® and BluePrint® Read More
AUTHORS: Adam M. Brufsky, Jennifer A. Crozier, Ian Grady, Thomas Read More
PRESS RELEASE Oncology Consultants Join Agendia’s FLEX Big DataRegistry Study, Read More
PRESS RELEASE Latest Results from the I-SPY 2 Trial at Read More
PRESS RELEASE Agendia Announces Level 1 Inclusion of MammaPrint® Breast Read More
For the first time, early-stage breast cancer patients and their Read More
Dataset of up to 10,000 full genome profiles matched with Read More
As we close out the first half of 2018, I’d Read More
IRVINE, CA and AMSTERDAM, NETHERLANDS – 25 July 2018 – Read More